Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon

Myeloid‐derived suppressor cells (MDSCs) and CD4+ regulatory T cells (Tregs) expand during chronic hepatitis B virus (HBV) infection and inhibit antiviral immunity. However, the relationship between antiviral effect and the frequencies of those immune suppressive cells after pegylated interferon α‐2a (PegIFNα‐2a) therapy is not clearly understood. This study aimed to investigate the contribution of monocytic MDSCs (mMDSCs) and CD4+ Tregs to functional cure (HBsAg seroclearance) after PegIFNα‐2a therapy and evaluate the effect of PegIFNα‐2a therapy on these cells.

[1]  B. Chakraborty,et al.  Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing , 2022, Hepatology.

[2]  M. Isogawa,et al.  HBV-Specific CD8+ T-Cell Tolerance in the Liver , 2021, Frontiers in Immunology.

[3]  T. Asselah,et al.  Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development. , 2020, Journal of hepatology.

[4]  Qi Zhang,et al.  Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  Jiming Zhang,et al.  Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection , 2019, PLoS pathogens.

[6]  V. Wong,et al.  Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir – A prospective study , 2018, Journal of viral hepatitis.

[7]  Qiuju Han,et al.  5′‐triphosphate siRNA targeting HBx elicits a potent anti‐HBV immune response in pAAV‐HBV transfected mice , 2019, Antiviral research.

[8]  S. Kottilil,et al.  Chronic Hepatitis B Infection: A Review , 2018, JAMA.

[9]  M. Manns,et al.  Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss , 2018, The Journal of infectious diseases.

[10]  G. Foster,et al.  Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo , 2016, PLoS pathogens.

[11]  E. Shin,et al.  Immune responses and immunopathology in acute and chronic viral hepatitis , 2016, Nature Reviews Immunology.

[12]  Lin Li,et al.  Suppression of USP18 Potentiates the Anti-HBV Activity of Interferon Alpha in HepG2.2.15 Cells via JAK/STAT Signaling , 2016, PloS one.

[13]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[14]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[15]  I. Pacella,et al.  Divergent effects of type-I interferons on regulatory T cells. , 2015, Cytokine & growth factor reviews.

[16]  Jiayong Zhu,et al.  IFN-CSP Inhibiting Hepatitis B Virus in HepG2.2.15 Cells Involves JAK-STAT Signal Pathway , 2015, BioMed research international.

[17]  A. Bertoletti,et al.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections , 2015, Hepatology.

[18]  P. Lampertico,et al.  Optimal therapy of chronic hepatitis B: how do I treat my HBeAg‐negative patients? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[19]  R. Sun,et al.  γδT Cells Drive Myeloid-Derived Suppressor Cell–Mediated CD8+ T Cell Exhaustion in Hepatitis B Virus–Induced Immunotolerance , 2014, The Journal of Immunology.

[20]  M. Dijkgraaf,et al.  Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and Adefovir , 2013, Antiviral therapy.

[21]  K. Odunsi,et al.  Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling , 2013, The Journal of experimental medicine.

[22]  Austin Miller,et al.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. , 2013, Cancer research.

[23]  B. Bonnotte,et al.  Myeloid‐derived suppressor cells from tumor‐bearing mice impair TGF‐β‐induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25−FoxP3− T cells , 2012, Journal of leukocyte biology.

[24]  Y. Kondo,et al.  Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy , 2012, Journal of Gastroenterology.

[25]  P. Lampertico,et al.  Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. , 2012, Journal of hepatology.

[26]  T. Xing,et al.  Association of T regulatory cells with natural course and response to treatment with interferon-α in patients with chronic hepatitis B infection. , 2012, Chinese medical journal.

[27]  P. Krammer,et al.  Molecular Mechanisms of Treg-Mediated T Cell Suppression , 2012, Front. Immun..

[28]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[29]  N. Hayashi,et al.  Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients , 2012, Journal of Gastroenterology.

[30]  D. Tiniakos,et al.  Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. , 2011, Journal of hepatology.

[31]  N. Alonso,et al.  A prospective study of T‐ and B‐lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4+CD25+CD127low/−FoxP3+ T cells in patients with chronic HCV infection during pegylated interferon‐alpha2a plus ribavirin treatment , 2011, Journal of viral hepatitis.

[32]  G. Lesinski,et al.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy , 2011, Cancer Immunology, Immunotherapy.

[33]  V. Bronte,et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.

[34]  W. Liu,et al.  Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. , 2010, Antiviral research.

[35]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[36]  M. Manns,et al.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.

[37]  E. Wherry,et al.  Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. , 2008, Gastroenterology.

[38]  H. Kuo,et al.  HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. , 2007, Journal of biomedical science.

[39]  E. Kuipers,et al.  Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection , 2005, Hepatology.

[40]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[41]  C. Chu,et al.  Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. , 2002, Gastroenterology.

[42]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[43]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .